Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR DysregulationReportar como inadecuado

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Dysregulation of Fibroblast Growth Factor Receptor FGFR signaling through amplifications, mutations, and gene fusions has been implicated in a broad array of cancers e.g. liver, gastric, ovarian, endometrial, and bladder. ARQ 087 is a novel, ATP competitive, small molecule, multi-kinase inhibitor with potent in vitro and in vivo activity against FGFR addicted cell lines and tumors. Biochemically, ARQ 087 exhibited IC50 values of 1.8 nM for FGFR2, and 4.5 nM for FGFR1 and 3. In cells, inhibition of FGFR2 auto-phosphorylation and other proteins downstream in the FGFR pathway FRS2α, AKT, ERK was evident by the response to ARQ 087 treatment. Cell proliferation studies demonstrated ARQ 087 has anti-proliferative activity in cell lines driven by FGFR dysregulation, including amplifications, fusions, and mutations. Cell cycle studies in cell lines with high levels of FGFR2 protein showed a positive relationship between ARQ 087 induced G1 cell cycle arrest and subsequent induction of apoptosis. In addition, ARQ 087 was effective at inhibiting tumor growth in vivo in FGFR2 altered, SNU-16 and NCI-H716, xenograft tumor models with gene amplifications and fusions. ARQ 087 is currently being studied in a phase 1-2 clinical trial that includes a sub cohort for intrahepatic cholangiocarcinoma patients with confirmed FGFR2 gene fusions NCT01752920.

Autor: Terence G. Hall , Yi Yu, Sudharshan Eathiraj, Yunxia Wang, Ronald E. Savage, Jean-Marc Lapierre, Brian Schwartz, Giovanni Abbades



Documentos relacionados